These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 17000111)
1. Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome. Richards S; Sorensen B; Jae HS; Winn M; Chen Y; Wang J; Fung S; Monzon K; Frevert EU; Jacobson P; Sham H; Link JT Bioorg Med Chem Lett; 2006 Dec; 16(24):6241-5. PubMed ID: 17000111 [TBL] [Abstract][Full Text] [Related]
2. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). Sun D; Wang Z; Di Y; Jaen JC; Labelle M; Ma J; Miao S; Sudom A; Tang L; Tomooka CS; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP Bioorg Med Chem Lett; 2008 Jun; 18(12):3513-6. PubMed ID: 18511278 [TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome. Gu X; Dragovic J; Koo GC; Koprak SL; LeGrand C; Mundt SS; Shah K; Springer MS; Tan EY; Thieringer R; Hermanowski-Vosatka A; Zokian HJ; Balkovec JM; Waddell ST Bioorg Med Chem Lett; 2005 Dec; 15(23):5266-9. PubMed ID: 16185866 [TBL] [Abstract][Full Text] [Related]
4. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model. Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516 [TBL] [Abstract][Full Text] [Related]
5. The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Neelamkavil SF; Boyle CD; Chackalamannil S; Greenlee WJ; Zhang L; Terracina G Bioorg Med Chem Lett; 2009 Aug; 19(16):4563-5. PubMed ID: 19625185 [TBL] [Abstract][Full Text] [Related]
6. Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors. Shah U; Boyle CD; Chackalamannil S; Baker H; Kowalski T; Lee J; Terracina G; Zhang L Bioorg Med Chem Lett; 2010 Mar; 20(5):1551-4. PubMed ID: 20149650 [TBL] [Abstract][Full Text] [Related]
7. Discovery and optimization of benzenesulfonanilide derivatives as a novel class of 11β-HSD1 inhibitors. Rew Y; DeGraffenreid M; He X; Jaen JC; McMinn DL; Sun D; Tu H; Ursu S; Powers JP Bioorg Med Chem Lett; 2012 Jun; 22(11):3786-90. PubMed ID: 22542009 [TBL] [Abstract][Full Text] [Related]
8. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I. Roche D; Carniato D; Leriche C; Lepifre F; Christmann-Franck S; Graedler U; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E Bioorg Med Chem Lett; 2009 May; 19(10):2674-8. PubMed ID: 19395260 [TBL] [Abstract][Full Text] [Related]
9. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons. Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016 [TBL] [Abstract][Full Text] [Related]
10. Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. Su X; Vicker N; Ganeshapillai D; Smith A; Purohit A; Reed MJ; Potter BV Mol Cell Endocrinol; 2006 Mar; 248(1-2):214-7. PubMed ID: 16325333 [TBL] [Abstract][Full Text] [Related]
11. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056 [TBL] [Abstract][Full Text] [Related]
12. Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors. Odermatt A Expert Opin Ther Pat; 2009 Oct; 19(10):1477-83. PubMed ID: 19780703 [TBL] [Abstract][Full Text] [Related]
16. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling. Yang H; Dou W; Lou J; Leng Y; Shen J Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087 [TBL] [Abstract][Full Text] [Related]
17. Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Aster SD; Graham DW; Kharbanda D; Patel G; Ponpipom M; Santorelli GM; Szymonifka MJ; Mundt SS; Shah K; Springer MS; Thieringer R; Hermanowski-Vosatka A; Wright SD; Xiao J; Zokian H; Balkovec JM Bioorg Med Chem Lett; 2008 May; 18(9):2799-804. PubMed ID: 18434143 [TBL] [Abstract][Full Text] [Related]
18. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Boyle CD; Kowalski TJ Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274 [TBL] [Abstract][Full Text] [Related]
19. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds. Blum A; Favia AD; Maser E Mol Cell Endocrinol; 2009 Mar; 301(1-2):132-6. PubMed ID: 18822345 [TBL] [Abstract][Full Text] [Related]
20. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. Tu H; Powers JP; Liu J; Ursu S; Sudom A; Yan X; Xu H; Meininger D; Degraffenreid M; He X; Jaen JC; Sun D; Labelle M; Yamamoto H; Shan B; Walker NP; Wang Z Bioorg Med Chem; 2008 Oct; 16(19):8922-31. PubMed ID: 18789704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]